Cargando…
Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
Lefamulin is the first semisynthetic pleuromutilin being developed for oral and intravenous administration. The drug selectively inhibits prokaryotic ribosomal protein synthesis by binding to the peptidyl transferase centre via four H-bonds and other interactions, resulting in an ‘induced fit’ that...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449571/ https://www.ncbi.nlm.nih.gov/pubmed/30949709 http://dx.doi.org/10.1093/jac/dkz084 |